Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

S.-H.I. Ou(University of California, Irvine), Pasi A. Jänne(Dana-Farber Cancer Institute), Cynthia Huang Bartlett(Pfizer (United States)), Yiyun Tang(Pfizer (United States)), D.-W. Kim(Seoul National University Hospital), Gregory A. Otterson(The Ohio State University), Lucio Crinò(University of Perugia), Paulina Selaru(Pfizer (United States)), D. P. Cohen(Pfizer (United States)), Jeffrey W. Clark(Harvard University), Gregory J. Riely(Memorial Sloan Kettering Cancer Center)
Annals of Oncology
January 29, 2014
10.1093/annonc/mdt572
Cited by 220Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis